A recent study presented at the American College of Gastroenterology 2013 Annual Scientific Meeting demonstrates the cost-effectiveness of fecal microbiota transplantation for the treatment of C. difficile infection, according to an Infectious Disease Special Edition report.
C. difficile infections generate an annual economic burden of more than $1 billion. Traditional first line treatment includes antibiotics. Researchers found FMT to be more cost-effective than metronidazole and fidaxomicin.
The researchers concluded that C. difficile infection treatment guidelines should consider recommending use of FMT at an earlier time.
More Articles on Gastroenterology:
6 Statistics on Colorectal Cancer Diagnosis & Mortality
2014 Outlook: 7 Issues for Gastroenterologists to Focus on This Year
5 Things to Know About Advances in Oral Treatment for Hepatitis C
C. difficile infections generate an annual economic burden of more than $1 billion. Traditional first line treatment includes antibiotics. Researchers found FMT to be more cost-effective than metronidazole and fidaxomicin.
The researchers concluded that C. difficile infection treatment guidelines should consider recommending use of FMT at an earlier time.
More Articles on Gastroenterology:
6 Statistics on Colorectal Cancer Diagnosis & Mortality
2014 Outlook: 7 Issues for Gastroenterologists to Focus on This Year
5 Things to Know About Advances in Oral Treatment for Hepatitis C